DexCom, Inc. (NASDAQ:DXCM) Shares Sold by V Square Quantitative Management LLC

V Square Quantitative Management LLC lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,364 shares of the medical device company’s stock after selling 850 shares during the period. V Square Quantitative Management LLC’s holdings in DexCom were worth $650,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc acquired a new stake in DexCom in the fourth quarter valued at about $25,000. Riverview Trust Co lifted its position in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. Heck Capital Advisors LLC acquired a new stake in DexCom in the fourth quarter valued at about $38,000. RPg Family Wealth Advisory LLC purchased a new position in DexCom in the third quarter valued at about $57,000. Finally, Covestor Ltd increased its holdings in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on DXCM shares. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Raymond James dropped their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein increased their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 42,342 shares of company stock valued at $3,628,069. Company insiders own 0.30% of the company’s stock.

DexCom Stock Up 5.9 %

DXCM stock opened at $89.07 on Friday. The stock has a market capitalization of $34.79 billion, a P/E ratio of 53.34, a PEG ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a 50 day moving average price of $82.44 and a two-hundred day moving average price of $75.44.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. As a group, sell-side analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.